Reviewer’s report

Title: Methotrexate myelopathy after intrathecal chemotherapy: a case report

Version: 2
Date: 26 February 2015

Reviewer: Michael Linnebank

Which of the following best describes what type of case report this is?: Other

Another example of MTX-induced myelopathy.

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: Yes

Is there any missing information that you think must be added before publication?: No

Is this case worth reporting?: No

Is the case report persuasive?: Yes

Does the case report have explanatory value?: No

Does the case report have diagnostic value?: No

Will the case report make a difference to clinical practice?: No

Is the anonymity of the patient protected?: Yes

Comments to authors:

This is another case of MTX-induced myelopathy. The paper is well written, and the association of MTX and myelopathy is important, although not new. The case could have been improved by a search for genetic variants of homocysteine metabolism. The reference Ackermann et al is missing. In that paper, a therapeutic strategy against MTX-induced CNS damage is described, which was successful in the reported case. In the current work, therapy against myelopathy has not been tried, unfortunately.

Level of interest: An article whose findings are important to those with closely
related research interests

**Quality of written English:** Acceptable

**Declaration of competing interests:**

I declare that I have no competing interests.